Cargando…

The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide

OBJECTIVES: To investigate the clinical characteristics, adverse drug reactions, and outcomes of the oldest old patients (aged ≥80 years) with tuberculosis (TB) treated with rifampicin, isoniazid, and pyrazinamide (RIP)-containing regimens. DESIGN: A retrospective chart review study. SETTING: A 1,20...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Huang-Shen, Cheng, Chun-Wen, Lin, Ming-Shyan, Chou, Yen-Li, Chang, Pey-Jium, Lin, Jing-Chi, Ye, Jung-Jr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795580/ https://www.ncbi.nlm.nih.gov/pubmed/27042029 http://dx.doi.org/10.2147/CIA.S95411

Ejemplares similares

Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
por: Mukherjee, Aparna, et al.
Publicado: (2015)

Simultaneous Spectrophotometric Determination of Rifampicin, Isoniazid and Pyrazinamide in a Single Step
por: Asadpour-Zeynali, Karim, et al.
Publicado: (2016)

Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis
por: Ruslami, Rovina, et al.
Publicado: (2022)

Pyrazinamide resistance in rifampicin discordant tuberculosis
por: Mvelase, Nomonde Ritta, et al.
Publicado: (2022)

Isoniazid, Pyrazinamide and Rifampicin Content Variation in Split Fixed-Dose Combination Tablets
por: Pouplin, Thomas, et al.
Publicado: (2014)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study
por: Ramachandran, Geetha, et al.
Publicado: (2023)

Optimization of SABRE for polarization of the tuberculosis drugs pyrazinamide and isoniazid
por: Zeng, Haifeng, et al.
Publicado: (2013)

Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of Mycobacterium tuberculosis Infection
por: Sibley, Laura, et al.
Publicado: (2022)

A Case of Delusional Disorder With Abuse of Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol, the First-Line Anti-tuberculosis Therapy Drugs in India
por: Sathiyamoorthi, Sathiyanarayanan, et al.
Publicado: (2023)

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
por: Somoskovi, Akos, et al.
Publicado: (2001)

Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis
por: Pouplin, Thomas, et al.
Publicado: (2016)

Theoretically Guided Analytical Method Development and Validation for the Estimation of Rifampicin in a Mixture of Isoniazid and Pyrazinamide by UV Spectrophotometer
por: Khan, Mohammad F., et al.
Publicado: (2017)

A Simple and Sensitive UPLC–UV Method for Simultaneous Determination of Isoniazid, Pyrazinamide, and Rifampicin in Human Plasma and Its Application in Therapeutic Drug Monitoring
por: Jiang, Zhimei, et al.
Publicado: (2022)

Damage of testicular cell macromolecules and reproductive capacity of male rats following co-administration of ethambutol, rifampicin, isoniazid and pyrazinamide
por: Shayakhmetova, Ganna Mykhailivna, et al.
Publicado: (2012)

A case of thrombocytopenia caused by rifampicin and pyrazinamide
por: Bansal, Rekha, et al.
Publicado: (2013)

Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients
por: Kumar, A. K. Hemanth, et al.
Publicado: (2018)

No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients
por: Nardotto, Glauco Henrique Balthazar, et al.
Publicado: (2021)

Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania
por: Juma, Saumu Pazia, et al.
Publicado: (2019)

Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis
por: Brindle, Richard, et al.
Publicado: (2001)

Fatal poisoning by isoniazid and rifampicin
por: Sridhar, A., et al.
Publicado: (2012)

Isoniazid- and rifampicin-induced thrombocytopenia
por: Yakar, Fatih, et al.
Publicado: (2013)

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
por: Van Deun, Armand, et al.
Publicado: (2020)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy
por: Villa, Simone, et al.
Publicado: (2019)

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
por: Rockwood, Neesha, et al.
Publicado: (2016)

Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19
por: Tahseen, Sabira, et al.
Publicado: (2020)

Treating More with Less: Effectiveness and Event Outcomes of Antituberculosis Fixed-dose Combination Drug versus Separate-drug Formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for Pulmonary Tuberculosis Patients in Real-world Clinical Practice
por: Lai, Jacqueline Mui Lan, et al.
Publicado: (2019)

Development of a HPLC Method for Analysis of a Combination of Clofazimine, Isoniazid, Pyrazinamide, and Rifampicin Incorporated into a Dermal Self-Double-Emulsifying Drug Delivery System
por: van Staden, Daniélle, et al.
Publicado: (2023)

Mutations in Efflux Pump Rv1258c (Tap) Cause Resistance to Pyrazinamide, Isoniazid, and Streptomycin in M. tuberculosis
por: Liu, Jiayun, et al.
Publicado: (2019)

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
por: Kaboggoza, Julian P, et al.
Publicado: (2019)

Diagnostic performance of DNA microarray for detecting rifampicin and isoniazid resistance in Mycobacterium tuberculosis
por: Sun, Bingqi, et al.
Publicado: (2021)

Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania
por: Denti, Paolo, et al.
Publicado: (2015)

Mechanochemical Synthesis and Physicochemical Characterization of Isoniazid and Pyrazinamide Co-crystals With Glutaric Acid
por: Ngilirabanga, Jean Baptiste, et al.
Publicado: (2020)

Acquired Resistance to Isoniazid During Isoniazid Monotherapy in a Subject with Latent Infection Following Household Rifampicin-Resistant Tuberculosis Contact: A Case Report
por: Li, Tsung-Lun, et al.
Publicado: (2021)

Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence
por: Rockwood, Neesha, et al.
Publicado: (2017)

Stability Study of Isoniazid and Rifampicin Oral Solutions Using Hydroxypropyl-Β-Cyclodextrin to Treat Tuberculosis in Paediatrics
por: Santoveña-Estévez, Ana, et al.
Publicado: (2020)

Evaluation of Biochip System in Determining Isoniazid and Rifampicin Resistances of Mycobacterium Tuberculosis in Sputum Samples
por: Lu, Wei, et al.
Publicado: (2012)

Systems Pharmacology Approach Toward the Design of Inhaled Formulations of Rifampicin and Isoniazid for Treatment of Tuberculosis
por: Cilfone, NA, et al.
Publicado: (2015)

Rapid Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using Real-Time PCR
por: Sahebi, Leyla, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_oep5018l3hempp0u14rrudhld1